Avital Angel-Korman1, Aala Jaberi1, Vaishali Sanchorawala2,3, Andrea Havasi1,3. 1. Renal Section, Department of Medicine, Boston Medical Center, Boston, MA, USA. 2. Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA. 3. Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
Abstract
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosis patients in complete (CR) or very good partial hematologic response (VGPR) but with renal organ relapse is not clear. Methods: We present eight patients with AL amyloidosis who had a repeat kidney biopsy performed. Results: AL amyloidosis was initially diagnosed by a kidney biopsy. All patients had a favorable response to treatment (CR/VGPR) and five of them also had initially a renal organ response. A repeat kidney biopsy was done due to gradual deterioration of kidney function and/or proteinuria while maintaining a hematologic response. Repeat kidney biopsies showed findings consistent with amyloid deposits in all patients. Seven patients had renal progression with four of them requiring dialysis initiation. Only one patient had a favorable renal outcome. This patient had subacute kidney injury with decreasing proteinuria and was found to have granulomatous interstitial nephritis in addition to amyloid deposits and responded well to steroid treatment with rapid improvement in renal function.Conclusions: In AL amyloidosis patients who achieve a favorable hematologic response to treatment (CR/VGPR) but subsequently develop worsening renal insufficiency or proteinuria, a repeat kidney biopsy should generally not be performed. Amyloid deposits persist in the kidneys even after successful hematologic treatment and it is impossible to differentiate between new versus old amyloid deposits, which makes performing a repeat kidney biopsy unnecessary in most cases. Demonstration of amyloid deposits on repeat kidney biopsy would not aid in the decision making regarding re-initiation of hematologic treatment. A kidney biopsy should be considered only in cases when a specific alternative diagnosis is suspected.
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosispatients in complete (CR) or very good partial hematologic response (VGPR) but with renal organ relapse is not clear. Methods: We present eight patients with AL amyloidosis who had a repeat kidney biopsy performed. Results:AL amyloidosis was initially diagnosed by a kidney biopsy. All patients had a favorable response to treatment (CR/VGPR) and five of them also had initially a renal organ response. A repeat kidney biopsy was done due to gradual deterioration of kidney function and/or proteinuria while maintaining a hematologic response. Repeat kidney biopsies showed findings consistent with amyloid deposits in all patients. Seven patients had renal progression with four of them requiring dialysis initiation. Only one patient had a favorable renal outcome. This patient had subacute kidney injury with decreasing proteinuria and was found to have granulomatous interstitial nephritis in addition to amyloid deposits and responded well to steroid treatment with rapid improvement in renal function.Conclusions: In AL amyloidosispatients who achieve a favorable hematologic response to treatment (CR/VGPR) but subsequently develop worsening renal insufficiency or proteinuria, a repeat kidney biopsy should generally not be performed. Amyloid deposits persist in the kidneys even after successful hematologic treatment and it is impossible to differentiate between new versus old amyloid deposits, which makes performing a repeat kidney biopsy unnecessary in most cases. Demonstration of amyloid deposits on repeat kidney biopsy would not aid in the decision making regarding re-initiation of hematologic treatment. A kidney biopsy should be considered only in cases when a specific alternative diagnosis is suspected.
Authors: Eli Muchtar; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; David Dingli; Francis K Buadi; Martha Grogan; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Wilson Gonsalves; Rahma Warsame; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri Journal: Blood Date: 2017-01-26 Impact factor: 22.113
Authors: Eli Muchtar; Angela Dispenzieri; Nelson Leung; Martha Q Lacy; Francis K Buadi; David Dingli; Martha Grogan; Suzanne R Hayman; Prashant Kapoor; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Rajshekhar Chakraborty; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar; Morie A Gertz Journal: Leukemia Date: 2018-02-20 Impact factor: 11.528
Authors: Gregory P Kaufman; Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Nelson Leung; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Steven R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar Journal: Am J Hematol Date: 2015-01-16 Impact factor: 10.047
Authors: Hanni Menn-Josephy; Carol S Lee; Angela Nolin; Marta Christov; Denis V Rybin; Janice M Weinberg; Joel Henderson; Ramon Bonegio; Andrea Havasi Journal: Am J Nephrol Date: 2016-09-15 Impact factor: 3.754
Authors: Martin Zeier; Jolanta Perz; Reinhold P Linke; Ugo Donini; Rüdiger Waldherr; Konrad Andrassy; Anthony D Ho; Hartmut Goldschmidt Journal: Nephrol Dial Transplant Date: 2003-12 Impact factor: 5.992
Authors: J Flores-Montero; L Sanoja-Flores; B Paiva; N Puig; O García-Sánchez; S Böttcher; V H J van der Velden; J-J Pérez-Morán; M-B Vidriales; R García-Sanz; C Jimenez; M González; J Martínez-López; A Corral-Mateos; G-E Grigore; R Fluxá; R Pontes; J Caetano; L Sedek; M-C Del Cañizo; J Bladé; J-J Lahuerta; C Aguilar; A Bárez; A García-Mateo; J Labrador; P Leoz; C Aguilera-Sanz; J San-Miguel; M-V Mateos; B Durie; J J M van Dongen; A Orfao Journal: Leukemia Date: 2017-01-20 Impact factor: 11.528